Wei-Wei Zuo
Chun-Fang Zhao3†
Yue-Ping Liu
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China
- 2Department of Gynecology, Tangshan People’s Hospital, Tangshan, China
- 3Department of Histoplasty and Embryology, Hebei Medical University, Shijiazhuang, China
- 4Department of Molecular Biology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China
- 5Department of gastrointestinal surgery, Tangshan People’s Hospital, Tangshan, China
- 6Department of Pathology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China
by Zuo W-W, Zhao C-F, Li Y, Sun H-Y, Ma G-M, Liu Y-P and Kang S (2022) Front. Oncol. 12:931445. doi: 10.3389/fonc.2022.931445
In the published article, there was an error in the Funding statement. The Grant number for the Natural Science Foundation of Hebei Province was displayed as “H20202063”. The correct Funding statement appears below.
The correct Funding statement is “This work was supported by grants from the Natural Science Foundation of Hebei Province (Grant number: H2020206385).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: advanced epithelial ovarian cancer, PARP1, cytokeratin, platinum resistance, prognosis
Citation: Zuo W-W, Zhao C-F, Li Y, Sun H-Y, Ma G-M, Liu Y-P and Kang S (2023) Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer. Front. Oncol. 13:1218746. doi: 10.3389/fonc.2023.1218746
Received: 08 May 2023; Accepted: 16 May 2023;
Published: 27 June 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Zuo, Zhao, Li, Sun, Ma, Liu and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shan Kang, a3NqcTYyY25Ac2luYS5jb20=
†These authors have contributed equally to this work